For example, preclinical studies demonstrate a superior killing effect with a bispecific ADC targeting both HER2 and prolactin receptor in breast cancer cells that co-express each target due to the enhanced internalization of prolactin receptor [56]. This evidence concerns the gene ERBB2 and breast cancer.